SAN DIEGO, Aug. 24, 2015 /PRNewswire/ -- Beloteca, Inc., a specialty pharmaceutical company focused on the development of sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations, is pleased to announce the appointment of Dorla Mirejovsky, Ph.D. as Chief Scientific Officer.
"We are excited to have Dorla join Beloteca; she is a terrific addition to the team we are building," stated Fred Defesche, Chief Executive Officer of Beloteca, Inc. "Dorla's expertise in developing sterile based pharmaceuticals strengthens the capabilities of Beloteca."
Dr. Mirejovsky brings more than 30 years of pharmaceutical development experience to Beloteca. Dr. Mirejovsky has contributed to the development and commercialization of more than 60 products. She has served in product development roles of increasing responsibility for leading companies such as Allergan, Isis Pharmaceuticals, Sicor Pharmaceuticals, Spectrum Pharmaceuticals and Avrio Biopharma. Dorla joins Beloteca from Avrio Biopharma where she was responsible for the formulation department which supported more than 30 formulation products for various pharmaceutical clients.
"I am very excited to join Beloteca, and look forward to contributing to the development of Beloteca's business," stated Dorla Mirejovsky, Chief Scientific Officer of Beloteca.
Beloteca is a privately held specialty pharmaceutical company. Beloteca's primary focus is to develop and obtain regulatory approval sterile pharmaceutical products with an emphasis on generics and 505(b)(2) reformulations. We target niche and difficult to manufacture products. For additional information about the Company, visit the Company's web site at www.beloteca.com.
For further information, please contact Fred Defesche at 512-669-8765 or via email at [email protected]